Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Reply to Correspondence

Reply to correspondence on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Chen-Hua Liu, Yu-Ping Chang

Clin Mol Hepatol. 2025;31(2):e232-e233. Published online February 26, 2025

DOI: https://doi.org/10.3350/cmh.2025.0203

View: 730 Download: 22

Correspondence

Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):e203-e205. Published online February 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0179

View: 739 Download: 19 Web of Science: 1 Crossref: 1

Original Article

Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C

Tom Ryu, Young Chang, Soung Won Jeong, Jeong-Ju Yoo, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):548-562. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.0904

View: 1734 Download: 119 Web of Science: 4 Crossref: 1

Review

Acute hepatitis C virus infection: clinical update and remaining challenges

Chen-Hua Liu, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(3):623-642. Published online February 20, 2023

DOI: https://doi.org/10.3350/cmh.2022.0349

View: 8958 Download: 508 Web of Science: 29 Crossref: 32

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy

Chung-Feng Huang, Ming-Lung Yu

Clin Mol Hepatol. 2020;26(3):251-260. Published online March 19, 2020

DOI: https://doi.org/10.3350/cmh.2020.0018

View: 16239 Download: 396 Web of Science: 46 Crossref: 48

Discussion on critical points for a tailored therapy to cure hepatitis C virus infection

Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti

Clin Mol Hepatol. 2019;25(1):30-36. Published online January 23, 2019

DOI: https://doi.org/10.3350/cmh.2018.0061

View: 8893 Download: 158 Web of Science: 16 Crossref: 18

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals

Soon Young Ko, Won Hyeok Choe

Clin Mol Hepatol. 2018;24(4):351-357. Published online March 16, 2018

DOI: https://doi.org/10.3350/cmh.2017.0063

View: 11030 Download: 355 Web of Science: 4 Crossref: 1

Management of direct antiviral agent failures

María Buti, Rafael Esteban

Clin Mol Hepatol. 2016;22(4):432-438. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0107

View: 12398 Download: 366 Web of Science: 31 Crossref: 29

Original Article

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection

Hee Chul Nam, Hae Lim Lee, Hyun Yang, Myeong Jun Song

Clin Mol Hepatol. 2016;22(2):259-266. Published online June 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0020

View: 10560 Download: 170 Web of Science: 8 Crossref: 7

Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea

Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim

Clin Mol Hepatol. 2015;21(4):358-364. Published online December 24, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.4.358

View: 9339 Download: 111 Web of Science: 12 Crossref: 11

Reply to Correspondence

SHOULD DIRECT-ACTING ANTIVIRAL BE CONSIDERED FOR ALL PATIENTS WITH HCV-RELATED HEPATOCELLULAR CARCINOMA?

Yan Ling ONG, Apichat KAEWDECH, Yu Jun WONG

Received March 5, 2025 Accepted March 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0257 [Accepted]

View: 392 Download: 13

Original Article

Distinct Inflammatory Imprint in Non-Cirrhotic and Cirrhotic Patients Before and After Direct-Acting Antiviral Therapy

Moana Witte, Carlos Oltmanns, Jan Tauwaldt, Hagen Schmaus, Jasmin Mischke, Gordon Grabert, Mara Bretthauer, Lennart M. Roesner, Thomas Werfel, Katja Deterding, Benjamin Maasoumy, Heiner Wedemeyer, Tim Kacprowski, Anke R.M. Kraft, Markus Cornberg

Received March 20, 2025 Accepted June 2, 2025

DOI: https://doi.org/10.3350/cmh.2025.0292 [Accepted]

View: 485 Download: 46

1 |

Viewed By 12500	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7615	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 7079	MAFLD: How is it different from NAFLD?
Viewed By 5670	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5543	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 366	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 354	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search